Literature DB >> 19470514

Antiretroviral drug resistance in human immunodeficiency virus type 2.

Michel L Ntemgwa1, Thomas d'Aquin Toni, Bluma G Brenner, Ricardo J Camacho, Mark A Wainberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19470514      PMCID： PMC2737883          DOI： 10.1128/AAC.00154-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  91 in total

1.  Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.

Authors:  Louise Doyon; Sonia Tremblay; Lise Bourgon; Elizabeth Wardrop; Michael G Cordingley
Journal:  Antiviral Res       Date:  2005-10       Impact factor: 5.970

Review 2.  The clinical significance of viral fitness.

Authors:  Anna Maria Geretti
Journal:  J HIV Ther       Date:  2005-03

3.  Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news?

Authors:  Serge Eholié; Xavier Anglaret
Journal:  Int J Epidemiol       Date:  2006-07-17       Impact factor: 7.196

4.  Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level.

Authors:  Urvi M Parikh; Douglas C Barnas; Hawazin Faruki; John W Mellors
Journal:  J Infect Dis       Date:  2006-07-24       Impact factor: 5.226

5.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2.

Authors:  Mario L Santiago; Friederike Range; Brandon F Keele; Yingying Li; Elizabeth Bailes; Frederic Bibollet-Ruche; Cecile Fruteau; Ronald Noë; Martine Peeters; John F Y Brookfield; George M Shaw; Paul M Sharp; Beatrice H Hahn
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2.

Authors:  Maarten F Schim van der Loeff; Akum Aveika Awasana; Ramu Sarge-Njie; Marianne van der Sande; Assan Jaye; Saihou Sabally; Tumani Corrah; Samuel J McConkey; Hilton C Whittle
Journal:  Int J Epidemiol       Date:  2006-03-16       Impact factor: 7.196

8.  Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

Authors:  Berta Rodés; Julie Sheldon; Carlos Toro; Victoria Jiménez; Miguel Angel Alvarez; Vincent Soriano
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

9.  Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia.

Authors:  Sabelle Jallow; Steve Kaye; Abraham Alabi; Akum Aveika; Ramu Sarge-Njie; Saihou Sabally; Tumani Corrah; Hilton Whittle; Guido Vanham; Sarah Rowland-Jones; Wouter Janssens; Samuel J McConkey
Journal:  AIDS       Date:  2006-06-26       Impact factor: 4.177

10.  Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

Authors:  Paul L Boyer; Stefan G Sarafianos; Patrick K Clark; Eddy Arnold; Stephen H Hughes
Journal:  PLoS Pathog       Date:  2006-02-17       Impact factor: 6.823
View more
  37 in total

Review 1.  Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.

Authors:  Maxwell O Akanbi; Kimberly K Scarsi; Kimberly Scarci; Babafemi Taiwo; Robert L Murphy
Journal:  Expert Opin Pharmacother       Date:  2012-01       Impact factor: 3.889

2.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  HIV testing updates and challenges: when regulatory caution and public health imperatives collide.

Authors:  Bernard M Branson
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

5.  Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.

Authors:  Mar Álvarez; María Nevot; Jesús Mendieta; Miguel A Martínez; Luis Menéndez-Arias
Journal:  J Biol Chem       Date:  2017-12-22       Impact factor: 5.157

6.  HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?

Authors:  Daniela Francisci; Laura Martinelli; Liliana E Weimer; Maurizio Zazzi; Marco Floridia; Giulia Masini; Franco Baldelli
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

7.  HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.

Authors:  Paul L Boyer; Patrick K Clark; Stephen H Hughes
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

8.  A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Shengwen Xiong; Pedro Borrego; Xiaohui Ding; Yuanmei Zhu; Andreia Martins; Huihui Chong; Nuno Taveira; Yuxian He
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

9.  Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.

Authors:  Geoffrey Férir; Dana Huskens; Kenneth E Palmer; Daniel M Boudreaux; Michael D Swanson; David M Markovitz; Jan Balzarini; Dominique Schols
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

10.  Genotypic resistance profiles of HIV-2-treated patients in West Africa.

Authors:  Charlotte Charpentier; Serge Eholié; Xavier Anglaret; Mélanie Bertine; Christine Rouzioux; Véronique Avettand-Fenoël; Eugène Messou; Albert Minga; Florence Damond; Jean-Christophe Plantier; François Dabis; Gilles Peytavin; Françoise Brun-Vézinet; Didier K Ekouevi
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.